Clinical trials: Recurrent Plasma Cell Myeloma
Relapsed or Refractory Multiple Myeloma
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate the safety and tolerability of mRNA-2808 in participants with relapsed or refractory multiple myeloma (RRMM).
- Trial name
- NCT07116616
- Testing
- mRNA-2808
- Where
- 10 sites in United States
- Volunteers
- 190 people
- Sponsor
- ModernaTX, Inc.
Relapsed or Refractory Multiple Myeloma
mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
This study is designed to evaluate the safety and tolerability of mRNA-2736 in participants with RRMM.
- Trial name
- NCT05918250
- Testing
- mRNA-2736
- Where
- 13 sites in United States, Canada
- Sponsor
- ModernaTX, Inc.
Multiple Myeloma in Relapse, Refractory Multiple Myeloma
Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma
This is a Phase 1 clinical trial to evaluate a new combination of drugs for the treatment of relapsed or refractory (drug-resistant) multiple myeloma.
- Conditions
- Multiple Myeloma in Relapse, Refractory Multiple Myeloma, Multiple Myeloma
- Trial name
- NCT02103335
- Testing
- pomalidomide, marizomib, low-dose dexamethasone
- Where
- 6 sites in United States, Australia
- Volunteers
- 38 people
- Sponsor
- Celgene
Multiple Myeloma
A Study of JNS002 (Doxorubicin Hydrochloride Liposome Injection) in Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate tolerability of the combination therapy of JNS002 and bortezomib in Japanese bortezomib-naive patients with multiple myeloma who have ever received at least 1 line of chemotherapy.
- Trial name
- NCT01371227
- Testing
- JNS002
- Where
- 2 sites in Japan
- Volunteers
- 3 people
- Sponsor
- Janssen Pharmaceutical K.K.
Relapsed or Refractory Multiple Myeloma
A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
This is a single - arm, multi - cohort, open - label, multi - center Phase II clinical study. It aims to evaluate the efficacy and safety of F182112 combined with different administration regimens in patients with relapsed or…
- Trial name
- NCT07312188
- Testing
- F182112+P, F182112+CD38
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
Multiple Myeloma
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.
- Trial name
- NCT03989414
- Testing
- CC-92480, Bortezomib, Dexamethasone
- Where
- 49 sites in United States, Canada and 7 more
- Volunteers
- 424 people
- Sponsor
- Celgene
Multiple Myeloma, Relapsed and Refractory Multiple Myeloma
A Study of HG146 Capsule in Chinese Subjects with Relapsed and Refractory Multiple Myeloma
This study is designed to evaluate the tolerability and safety of HG146 capsule in patients with multiple myeloma.
- Trial name
- NCT03710915
- Testing
- HG146
- Where
- China
- Volunteers
- 3 people
- Sponsor
- HitGen Inc.
Leukemia, Myelodysplastic Syndromes
Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant
A Phase I study of BPX-501 T cell infusion in adults with recurrent or minimal residual disease (MRD) hematologic malignancies post-allogeneic transplant.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Lymphoma, Multiple Myeloma
- Trial name
- NCT02477878
- Testing
- BPX-501, Rimiducid
- Where
- 5 sites in United States
- Volunteers
- 10 people
- Sponsor
- Bellicum Pharmaceuticals
Multiple Myeloma, Multiple Myeloma in Relapse
Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients
This is a phase I/II study of perifosine in combination with bortezomib-with or without dexamethasone-for patients with relapsed or refractory multiple myeloma previously treated with bortezomib.
- Trial name
- NCT00401011
- Testing
- Perifosine, Bortezomib, Dexamethasone
- Volunteers
- 84 people
- Sponsor
- AEterna Zentaris
Plasma Cell Myeloma Recurrent
SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM
This will be randomized, multicenter, Phase 3, open-label study evaluating subcutaneous (SC) vs intravenous (IV) administration of isatuximab in combination with pomalidomide and dexamethasone (Pd) in RRMM patients (study…
- Trial name
- IRAKLIA (NCT05405166)
- Testing
- Isatuximab IV, Isatuximab SC, Dexamethasone
- Where
- 128 sites in United States, Argentina and 19 more
- Volunteers
- 531 people
- Sponsor
- Sanofi
Relapsed or Refractory Multiple Myeloma (RRMM)
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.
- Trial name
- NCT06615479
- Testing
- BMS-986393, Cyclophosphamide, Fludarabine
- Where
- 141 sites in United States, Argentina and 29 more
- Volunteers
- 440 people
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Multiple Myeloma
A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
The main purpose of the study is to evaluate the safety and tolerability of the combination of elranatamab and carfilzomib and dexamethasone or elranatamab and maplirpacept. There are 2 parts to this study.
- Trial name
- MagnetisMM-20 (NCT05675449)
- Testing
- Elranatamab, Carfilzomib, Maplirpacept
- Where
- 36 sites in United States, Israel
- Volunteers
- 59 people
- Sponsor
- Pfizer
Relapsed or Refractory Multiple Myeloma
A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
This study aims to provide a basis for further clinical development of YKST02. YKST02 is a study medicine that targets multiple myeloma and activates the human body to fight against this disease.
- Trial name
- NCT06574568
- Testing
- YKST02
- Where
- 12 sites in China
- Volunteers
- 70 people
- Sponsor
- Excyte Biopharma Ltd
Multiple Myeloma
Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma
To evaluate the safety and efficacy of Human BCMA Targeted T Cells Injection for the treatment of BCMA-positive relapsed/refractory multiple myeloma.
- Trial name
- NCT04003168
- Testing
- Human BCMA targeted T Cells Injection
- Where
- 3 sites in China
- Volunteers
- 18 people
- Sponsor
- Hrain Biotechnology Co., Ltd.
Multiple Myeloma
Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma
The purpose of this study is to investigate the anti-myeloma effect of panobinostat given at two different doses (10 mg and 20 mg oral) in combination with carfilzomib (20/56 mg/m2 i.v.) and low dose dexamethasone (20 mg oral) vs…
- Trial name
- PANORAMA-5 (NCT02756663)
- Testing
- panobinostat (capsules), carfilzomib (infusion), dexamethasone (tablets)
- Sponsor
- Novartis Pharmaceuticals
Relapsed or Refractory Multiple Myeloma
Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma
This study is a single-center, open and dose-escalation clinical study to evaluate the safety, tolerability, PK/PD characteristics and preliminary efficacy of the investigational drug O\&D-001 injection in the treatment of…
- Trial name
- NCT07369895
- Testing
- Chimeric antigen receptor T cell O&D-001 injection targeting BCMA and GPRC5D
- Where
- China
- Volunteers
- 18 people
- Sponsor
- O&D BioTech Group CO., Limited
Refractory, Multiple Myeloma
A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients
The purpose of this study is to assess the safety/tolerability and determine the Japanese recommended dose (RD) of bortezomib administered as a once-daily intravenous bolus twice weekly for 2 consecutive weeks(Days 1, 4, 8, and…
- Conditions
- Refractory, Multiple Myeloma, Relapse
- Trial name
- NCT00752518
- Testing
- bortezomib
- Volunteers
- 35 people
- Sponsor
- Janssen Pharmaceutical K.K.
Multiple Myeloma
IMGN901 in Combination With Lenalidomide and Dexamethasone
The purpose of this study is to test IMGN901 in combination with lenalidomide and dexamethasone every 28 days.
- Trial name
- NCT00991562
- Testing
- IMGN901
- Where
- 9 sites in United States
- Volunteers
- 50 people
- Sponsor
- ImmunoGen, Inc.
Multiple Myeloma
Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma
This is a phase II, multicenter, open label, nonrandomized study to evaluate the efficacy and safety of lenalidomide at a dose of 10 mg/dose in combination with bortezomib at 1.0 mg/m2/dose, pegylated liposomal doxorubicin (PLD)…
- Trial name
- NCT01160484
- Testing
- DVD-R
- Where
- 8 sites in United States
- Volunteers
- 40 people
- Sponsor
- Oncotherapeutics
Multiple Myeloma
Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma
This Phase 1, first-in-human (FIH), clinical study of CC-92328 will explore the safety, tolerability and preliminary biological and clinical activity of CC-92328 as a single-agent in the setting of relapsed and/or refractory…
- Trial name
- NCT04975399
- Testing
- CC-92328
- Where
- 15 sites in United States, Canada and 1 more
- Volunteers
- 26 people
- Sponsor
- Celgene